Skip to main content

Table 1 72 patients at study entry before treatment with Alirocumab or Evolocumab

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

Age at entry (years) Mean ± SD, [25th, 50th, 75th percentiles] 64.1 ± 9.6, [58, 65, 72]
BMI (kg/m2) Mean ± SD, [25th, 50th, 75th percentiles] 29.3 ± 5.1, [25.3, 29.0, 32.2]
Race 62 White (86%), 8 Black (11%), 1 Asian (1%), 1 Indian (1%)
Gender 45 F (63%), 27 M (38%)
Diabetes 12 Yes (17%), 60 No (83%)
Smoke 5 Yes (7%), 67 No (93%)
BP lowering drug 45 Yes (63%), 27 No (38%)
HeFH 47 Yes (65%), 25 No (35%); 25 had HeFH & no CVD (35%)
CVD 47 Yes (65%), 25 No (35%); 25 had CVD & no HeFH (35%)
Both HeFH & CVD 22 (31%)
Statin intolerant 42 Yes (58%), 30 No (42%)
Medication use at entry Statin only, N = 16
 Taking Statin (n = 30) Statin + ezetimibe, N = 5
Statin + colesevelam, N = 2
Statin + ezetimibe + colesevelam, N = 7
 Not taking statin (n = 42) Ezetimibe only, N = 4
Colesevelam only, N = 2
Ezetimibe + colesevelam, N = 5
Nothing, N = 31
Follow up weeks on ALI or EVO Mean ± SD, [25th, 50th, 75th percentiles] 26 ± 5, [24, 28]